Literature DB >> 21240874

Marked improvement by high-dose chemotherapy and autologous stem cell transplantation in a case of light chain deposition disease.

Keiichi Matsuzaki1, Isao Ohsawa, Tomohito Nishitani, Yukihiko Takeda, Hiroyuki Inoshita, Masaya Ishii, Miyuki Takagi, Satoshi Horikoshi, Yasuhiko Tomino.   

Abstract

A 55-year-old woman presented with heavy proteinuria (6.2 g/day) in April 2007. Because monoclonal IgG-k was detected in serum and urine samples, bone marrow aspiration and renal biopsy were performed. She was diagnosed with plasma cell dyscrasia because a bone marrow aspiration specimen showed plasma cells at 6.1%. Renal tissues revealed the formation of nodular glomerulosclerosis which was negative for Congo-red staining. Renal immunohistochemistry showed positive staining for kappa light chains in the nodular lesions, proximal tubules and part of Bowman's capsules. Her renal involvement was diagnosed as light chain deposition disease. Proteinuria disappeared and renal function stabilized after high-dose chemotherapy and autologous stem cell transplantation. It appears that an early initiation of active therapy such as high-dose chemotherapy and autologous stem cell transplantation may be beneficial for patients with light chain deposition disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21240874     DOI: 10.5301/jn.2011.6241

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  5 in total

1.  Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function.

Authors:  Paolo Milani; Marco Basset; Paola Curci; Andrea Foli; Rita Rizzi; Mario Nuvolone; Raffaella Guido; Loreto Gesualdo; Giorgina Specchia; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Adv       Date:  2020-04-14

2.  Natural history and outcome of light chain deposition disease.

Authors:  Rabya H Sayed; Ashutosh D Wechalekar; Janet A Gilbertson; Paul Bass; Shameem Mahmood; Sajitha Sachchithanantham; Marianna Fontana; Ketna Patel; Carol J Whelan; Helen J Lachmann; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2015-09-21       Impact factor: 22.113

3.  Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.

Authors:  Tomás J González-López; Lourdes Vázquez; Teresa Flores; Jesus Fernando San Miguel; Ramon García-Sanz
Journal:  Clin Pract       Date:  2011-11-23

4.  [Clinical features and prognosis of patients with primary light chain deposition disease].

Authors:  J N Wang; J Feng; X X Cao; M H Duan; L Zhang; D B Zhou; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

5.  Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy.

Authors:  Tânia Maia; Rui Bergantim; Henrique Costa; Jorge Pinheiro; Fernanda Trigo
Journal:  Clin Case Rep       Date:  2021-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.